Comparison of Morning Versus Evening Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response. The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.
• Patient aged over 18 years
• Patient with Rheumatoid Arthritis according to the 2010 ACR/EULAR criteria
• Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations
• Patient capable of providing informed, written, dated, and signed consent before the start of any trial-related procedure.